After a flurry of Big Pharma deals in the first week of the new year, the life sciences industry is heading to San Francisco ...

Now, the Chicago-based pharma is heading southwest as it charts the next leg of its stateside investment tour.

Bristol Myers Squibb is already aiming to launch more than 10 new medicines by 2030. | Bristol Myers Squibb is already aiming ...

In a preliminary report of its 2025 results, Apellis said that sales of its geographic atrophy (GA) drug Syfovre came in at ...

Cellares, the contract drugmaker known for its cell therapy factory-in-a-box, will expand its operations to Europe after ...

The FDA has issued a complete response letter for the partners’ application in EBV+PTLD, marking the agency’s second snub of ...

Camzyos, which works by blocking the actin-myosin interactions responsible for HCM and, in effect, relaxing the heart, bears ...

Mind Medicine has altered its state, rebranding as Definium Therapeutics ahead of a series of phase 3 data drops on its lead ...

Listening to patients is no longer a “nice to have” for life sciences companies—it is a strategic necessity that can ...

As Novartis turns the calendar on a new year, the Swiss drugmaker is elaborating further on plans for the $23 billion U.S.

Five months ago, J&J also revealed its plan to spend $2 billion over the next 10 years to operate a 160,000-square-foot ...

In an open-label phase 3b trial, the co-administration of Lilly’s IL-17A antagonist Taltz (ixekizumab) and dual GIP/GLP-1 ...